Bristol-Myers, Otsuka America Announce FDA Approves US Product Labeling Update for Sprycel to Include Three--Year First-Line, Five-Year Second-Line Efficacy, Safety Data in Chronic Myeloid Leukemia in Chronic Phase
Paul Quintaro